Milestone Pharmaceuticals Inc. (NASDAQ: MIST) Reports Earnings Beat Amid Launch Progress and Regulatory Timeline AdjustmentMIST reported an EPS of -$0.16 for Q4 2025, beating the consensus estimate of -$0.18 (by $0.02). This was a positive surprise relative to expectations.Revenue was approximately $1.5 million, which beat the prior consensus estimate of around $1.20 million for that period. The company announced a minor delay in the European approval timeline for etripamil (conditionally branded TACHYMIST™ ...